Reviewing iBio Inc. (IBIO)’s and Conatus Pharmaceuticals Inc. (NASDAQ:CNAT)’s results

Both iBio Inc. (NYSEAMERICAN:IBIO) and Conatus Pharmaceuticals Inc. (NASDAQ:CNAT) are each other’s competitor in the Biotechnology industry. Thus the contrast of their profitability, analyst recommendations, risk, dividends, earnings and valuation, institutional ownership.

Earnings & Valuation

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
iBio Inc. N/A 44.66 16.94M -1.39 0.00
Conatus Pharmaceuticals Inc. 34.98M 1.78 18.46M -0.61 0.00

Table 1 demonstrates iBio Inc. and Conatus Pharmaceuticals Inc.’s gross revenue, earnings per share and valuation.


Table 2 demonstrates the net margins, return on equity and return on assets of iBio Inc. and Conatus Pharmaceuticals Inc.

Net Margins Return on Equity Return on Assets
iBio Inc. 0.00% -164.6% -44.6%
Conatus Pharmaceuticals Inc. -52.77% -84% -26%

Risk and Volatility

iBio Inc. has a beta of 0.34 and its 66.00% less volatile than S&P 500. Conatus Pharmaceuticals Inc.’s 135.00% more volatile than S&P 500 which is a result of the 2.35 beta.

Analyst Ratings

The next table highlights the delivered recommendations and ratings for iBio Inc. and Conatus Pharmaceuticals Inc.

Sell Ratings Hold Ratings Buy Ratings Rating Score
iBio Inc. 0 0 0 0.00
Conatus Pharmaceuticals Inc. 0 1 0 2.00

Meanwhile, Conatus Pharmaceuticals Inc.’s consensus price target is $4, while its potential upside is 94.17%.

Institutional and Insider Ownership

Institutional investors held 6.7% of iBio Inc. shares and 32.8% of Conatus Pharmaceuticals Inc. shares. Insiders held roughly 45.3% of iBio Inc.’s shares. Competitively, insiders own roughly 3.67% of Conatus Pharmaceuticals Inc.’s shares.


Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
iBio Inc. -7.69% -8.86% -13.25% -45.86% -52% -59.35%
Conatus Pharmaceuticals Inc. -66.52% -71.54% -69.64% -66.14% -62.59% -67.53%

For the past year iBio Inc. was less bearish than Conatus Pharmaceuticals Inc.

iBio, Inc., a biotechnology company, focuses on developing and commercializing pharmaceutical product applications using its platform in the United States and internationally. Its lead therapeutic candidate is IBIO-CFB03 for the treatment of systemic scleroderma, idiopathic pulmonary fibrosis, and other fibrotic diseases. It is also developing vaccine candidates for third parties. The company has license and collaboration agreements with Caliber Biotherapeutics LLC and Fiocruz; and collaboration agreements with the A & M University System, AzarGen Biotechnologies (Pty) Ltd, Fraunhofer Center for Molecular Biotechnology, and Theoremdx, Inc. In addition, it offers a range of product and process development, analytical, and manufacturing services. iBio, Inc. is based in New York, New York.

Conatus Pharmaceuticals Inc., a biotechnology company, focuses on the development and commercialization of novel medicines to treat liver diseases in the United States. Its product candidates include Emricasan, an orally active pan-caspase protease inhibitor that is in Phase IIb clinical trials for patients with portal hypertension; for liver function; for patients liver fibrosis caused by nonalcoholic steatohepatitis; and for post-orthotopic liver transplant as a result of hepatitis C virus infection with sustained viral response. The company was founded in 2005 and is headquartered in San Diego, California.